Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 6, 2007, Pages 442-448

  Kokuho, Toshiharu ^a   Toya, Yoshiyuki ^a,h   Kawaguchi, Yoshiaki ^a   Tamura, Koichi ^a   Iwatsubo, Kousaku ^a   Dobashi, Yasushi ^b   Nakazawa, Akiko ^c   Takeda, Hideyuki ^d   Iwatsubo, Mizuka ^e   Hirawa, Nobuhito ^f   Yasuda, Gen ^f   Ohnishi, Toshimasa ^g   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kamiohoka Jinsei Clinic   (Japan)

^c Ottpama Jinsei Clinic   (Japan)

^d Division of Dialysis and Apheresis   (Japan)

^e Bunkojin Clinic   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g Kohsaikai Asahi Hospital   (Japan)

^h NONE   (Japan)

Author keywords

Bone disease; Hemodialysis; Hypercalcemia; Hypoparathyroidism; Sevelamer hydrochloride

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; OSTEOCALCIN; PARATHYROID HORMONE; SEVELAMER; VITAMIN D;

ABDOMINAL DISEASE; ADULT; AGED; ARTICLE; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; CALCIUM; CALCIUM PHOSPHATES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 36248955988     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00524.x     Document Type: Article

References (16)

1. Akigawa T, Kinugasa E, Akiba T et al. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int 1997 52 : S72 4.
2. Cannata Andia JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000 320 : 81 4.
3. Guh J-Y, Chen H-C, Chuang H-Y et al. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002 39 : 1245 54.
4. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997 29 : 641 9.
5. National Kidney Foundation. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications. Am J Kidney Dis 2003 42 : S1 202.
6. Iwasaki Y, Takami H, Tani M et al. Efficacy of Combined Sevelamer and Calcium Carbonate Therapy for Hyperphosphatemia in Japanese Hemodialysis Patients. Ther Apher Dial 2005 9 : 347 51.
7. Iseki K, Tozawa M, Takishita S. Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2003 18 : 782 7.
8. Kondo M, Hyodo T, Sakai T. Vitamin D3 withdrawal in hemodialysis patients with adynamic bone disease. Nephron 1998 80 : 89.
9. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005 16 : 2501 8.
10. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996 11 : 2430 8.
11. Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and Impaired Pituitary Response to Suppression and Stimulation in Chronic Renal Failure. J Clin Endocrinol Metab 1979 48 : 101 7.
12. Jara A, Bover J, Felsnfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 1995 47 : 1746 51.
13. Levy JR, Murray E, Manolagas S et al. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblast cells. Proc Natl Acad Sci USA 1999 96 : S505 10.
14. Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996 7 : 506 12.
15. Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephron Dial Transplant 1996 11 : 1065 72.
16. Malluche HH, Faugere MC, Fanti P et al. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984 26 : 869 74.